Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

BACKGROUND: Beyond their potent LDL (low‐density lipoprotein) cholesterol (LDL‐C)–lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors also reduce Lp(a) (lipoprotein[a]) levels by 25% to 30%, suggesting a 2:1 response ratio. We aimed to characterize the relati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Am Heart Assoc
Glavni autori: Shapiro, Michael D., Minnier, Jessica, Tavori, Hagai, Kassahun, Helina, Flower, Andrea, Somaratne, Ransi, Fazio, Sergio
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405654/
https://ncbi.nlm.nih.gov/pubmed/30755061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.010932
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items